ABEONA THERAPEUTICS INC. (ABEO) SEC Filings & Earnings Calls

Activist investor pressure

“The Reporting Persons became concerned regarding the Issuer's operational execution, the consistency of management's public statements with subsequent operating results, and the Issuer's governance.” · word for word

Revenue recognition risk due to manufacturing yield and lot release specifications

“Revenue was not recognized for two patients due to low manufacturing yield or not meeting lot release specifications.” · word for word

Cash burn rate; cash decreased from $191.4M to $146.8M in six months

“Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, compared to $191.4 million as of December 31, 2025.” · word for word

Dependence on ZEVASKYN revenue

“We have incurred significant operating losses and negative cash flows from operations since our inception and anticipate such losses and negative cash flows will continue until ZEVASKYN can provide sufficient revenue for us to be profitable and cash flow generating.” · word for word

Warrant liability volatility

“The change in fair value of warrant liabilities was a loss of $7.2 million for the three months ended June 30, 2026.” · word for word

No material risk; routine FD disclosure.

Continued operating losses and negative cash flow

“We have incurred significant operating losses and negative cash flows from operations since our inception and anticipate such losses and negative cash flows will continue until ZEVASKYN ® can provide sufficient revenue for us to be profitable and cash flow generating.” · word for word

Dependence on ZEVASKYN revenue for profitability

“We may incur losses for the next several years as we continue to invest in commercialization, product research and development, preclinical studies, clinical trials, and regulatory compliance and cannot assure that we will ever be able to generate sufficient product sales or royalty revenue to achieve profitability on a sustained basis, or at all.” · word for word

Commercial execution risk: ZEVASKYN revenue still early stage; QTC activation and patient onboarding pace critical.

“three patients completing treatment in the first quarter of 2026, one treatment to date in the second quarter” · word for word

Cash burn: $23M decrease in cash in Q1; ongoing operating losses may require future financing.

“Cash, cash equivalents and short-term investments totaled $168.3 million as of March 31, 2026, compared to $191.4 million as of December 31, 2025.” · word for word

Pipeline risk: ABO-701 is early stage (pre-clinical); IND filing not expected until H2 2027; no guarantee of clinical success.

“Abeona expects to file an Investigational New Drug (IND) application and commence first-in-human studies with ABO-701 in the second half of 2027” · word for word

Equity dilution from increased share reserve

“Potential dilution of 3,100,000 Shares as a Percentage of Fully Diluted Shares: 4.6%” · word for word

Reliance on equity compensation for talent retention

“If our stockholders do not approve the Plan Amendment we will be limited in our ability to continue to issue awards in numbers sufficient to attract and motivate the highly skilled employees” · word for word

Sustained operating losses and negative cash flow

“Excluding that gain, our net loss for the year ended December 31, 2025 would have been $81.2 million.” · word for word

Manufacturing quality issue

“costs associated with the August 2025 production of a full batch of ZEVASKYN® that could not be released due to technical issues that arose in implementing the rapid sterility lot release assay that was mandated by the FDA during BLA review.” · word for word

Dependence on single product for future revenue

“Our ability to achieve significant revenue or profitability depends upon our ability to commercialize ZEVASKYN® and complete the development of our drug candidates” · word for word

NOL limitation due to ownership change

“we determined that there were multiple ownership changes. As a result, certain NOL carryforwards will not be realizable due to the Section 382 limitations.” · word for word

Commercial launch still early; only one patient treated in 2025; manufacturing challenges with rapid sterility assay.

“First commercial patient treatment completed in December; costs from an August production batch not released due to technical challenges related to the FDA-mandated rapid sterility lot release assay.”

Commercial execution risk

“We may need to secure additional funding to carry out all of our planned research and development and potential commercialization activities.” · word for word

Manufacturing risk

“Although we produced bonafide drug product, it could not be released because a rapid sterility assay, mandated by the FDA as a release assay during the final stage of the Biologics License Application (BLA) review, initially yielded a false positive result for sterility.” · word for word

Dependence on single product

“We have incurred significant operating losses and negative cash flows from operations since our inception and anticipate such losses and negative cash flows will continue until ZEVASKYN® can provide sufficient revenue for us to be profitable and cash flow generating.” · word for word

Launch execution risk; first patient treatment delayed to Q4 2025 due to assay issue.

“First anticipated ZEVASKYN patient treatment shifted to 4Q 2025 following implementation of optimized release assay.” · word for word

Dependence on ZEVASKYN commercial success; no other revenue sources.

“No revenue reported; cash position sufficient for over two years without ZEVASKYN revenue.”